News
Company News: Curetis Publishes Interim Report for the First Half-Year 2018
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that further to its Half-Year Results Announcement made on 14 August 2018 it has filed its interim report for the first half year of 2018, including the half-year financial statements prepared in accordance with IAS 34 “Interim Financial Reporting, (the “Interim Statements”) with the Autoriteit Financiële Markten (the “AFM”) in the Netherlands today.
Company News: ISA Pharmaceuticals Reports Publication of Favorable Phase 2 Results of ISA101 plus Nivolumab in JAMA Oncology
ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced the publication of the results of a Phase 2 combination trial with ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody and PD-1 checkpoint inhibitor (NCT02426892). The open-label trial in patients with HPV-16 associated cancers demonstrated safety and efficacy, resulting in an improved survival as compared to historical nivolumab monotherapy results.
Company News Curetis To Attend Key Investor and Scientific Conferences In The Fourth Quarter 2018
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is scheduled to attend the following industry and investor conferences in the fourth quarter of 2018.
Company News: Anergis Initiates Development of Second-Generation COP Allergy Vaccines; Announces Publication of Sustained Efficacy Data from Ph. IIb Study Follow-up
— 2-month treatment with AllerT COP allergy vaccine provides sustained clinical benefit for more than one pollen season
— Research program to develop next-generation COP allergy vaccines in progress
Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has initiated the development of the second generation of its ultra-fast COP allergy vaccines. Moreover, the Company reported the publication of key proof-of-concept data from a clinical phase IIb follow-up trial demonstrating sustained clinical efficacy of its birch pollen vaccine AllerT for more than one pollen season. Read more…